Valganciclovir

A ganciclovir prodrug and antiviral agent that is used to treat CYTOMEGALOVIRUS RETINITIS in patients with AIDS, and for the prevention of CYTOMEGALOVIRUS INFECTIONS in organ transplant recipients who have received an organ from a CMV-positive donor.

Also Known As:

Networked: 656 relevant articles (103 outcomes, 72 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Razonable, Raymund R: 10 articles (01/2022 - 02/2004)
2.	Humar, Atul: 10 articles (01/2017 - 04/2004)
3.	Silveira, Fernanda P: 7 articles (09/2022 - 09/2010)
4.	Rahbar, Afsar: 7 articles (04/2022 - 10/2011)
5.	Stragliotto, Giuseppe: 7 articles (04/2022 - 09/2013)
6.	Amir, Jacob: 7 articles (01/2019 - 09/2010)
7.	Limaye, Ajit P: 6 articles (01/2022 - 06/2010)
8.	Rawlinson, William D: 6 articles (01/2022 - 03/2009)
9.	Singh, Nina: 6 articles (01/2022 - 01/2005)
10.	Wagener, Marilyn M: 6 articles (01/2022 - 01/2005)

Related Diseases

1.	Infections 01/01/2014 - "Valganciclovir (VGC) has been showed to be safe and highly effective in prophylaxis of CMV infection in RTx recipients. " 09/01/2011 - "To report a case of recurrent corneal graft failure because of cytomegalovirus (CMV) infection and to demonstrate successful clearance of the virus with oral valganciclovir, confirmed by polymerase chain reaction (PCR) assay. " 12/01/2021 - "Introduction: Observational studies suggest that low-dose valganciclovir prophylaxis (450 mg daily for normal renal function) is as effective as and perhaps safer than standard-dose valganciclovir (900 mg daily) in preventing CMV infection among kidney transplant recipients. " 07/01/2009 - ": She was started on valganciclovir, resulting in remission of her symptoms, improvement in inflammatory markers and clearing of detectable HHV8 viraemia : Valganciclovir is effective in treating symptomatic HHV8 infections without MCD." 10/01/2005 - "Valganciclovir is useful for the treatment of CMV infection and disease in selected organ-transplant recipients."
2.	Cytomegalovirus Infections (Inclusion Disease) 05/01/2021 - "Valganciclovir has been shown to improve hearing and neurodevelopmental outcomes in neonates with symptomatic congenital CMV infection. " 04/01/2020 - "In contrast, an open-label registry reported benefits for infants with congenital CMV infection and isolated hearing who received valganciclovir for 12 months, with hearing improvement in 2/3 of cases after a median follow-up of 4½ years. " 01/01/2020 - "Second, the treatment of congenital CMV infections with valganciclovir has beneficially improved both hearing and neurologic outcomes, both fundamental advances for these children. " 03/19/2019 - "Efficacy of Valganciclovir Treatment Depends on the Severity of Hearing Dysfunction in Symptomatic Infants with Congenital Cytomegalovirus Infection." 01/01/2019 - "In a previous study, we evaluated 1-year outcomes of using low-dose valganciclovir prophylaxis for cytomegalovirus infection in intermediate-risk kidney transplant recipients. "
3.	Retinitis 11/01/2004 - "Six months after discontinuation of immunosuppressive therapy, CMV retinitis of the left eye occurred but was treated successfully with a second course of oral valganciclovir. " 11/01/2022 - "Development and pharmacokinetic evaluation of osmotically controlled drug delivery system of Valganciclovir HCl for potential application in the treatment of CMV retinitis." 04/03/2021 - "There was no recurrence of retinitis/endotheliitis with a maintenance dose of oral valganciclovir. " 06/01/2020 - "Her retinitis gradually resolved after 3 months of treatment with valganciclovir, with no recurrence 4 months after discontinuing the valganciclovir. " 11/24/2011 - "Valganciclovir is an essential drug for developing successful programs for management of CMV retinitis in China and throughout SE Asia."
4.	Acquired Immunodeficiency Syndrome (AIDS) 04/01/2010 - "We describe the first case of an AIDS patient with CMV pseudotumor responding to oral treatment with valganciclovir with complete resolution of the CMV mass. " 07/05/2002 - "Cytomegalovirus-induced hemorrhagic cystitis in AIDS patient treated successfully with valganciclovir." 01/01/2014 - "Treatment may also be started with valganciclovir for CMV retinitis in AIDS patients. " 03/01/2005 - "Valganciclovir (VGC) has proved efficacious and safe for the prophylaxis against cytomegalovirus (CMV) in high-risk transplant recipients and for the treatment of CMV retinitis in AIDS patients. " 01/01/2001 - "To assess the incremental cost effectiveness of prophylaxis in the HAART era, data are needed on visual outcomes and utility for patients with CMV retinitis and AIDS, on better strategies for identifying subpopulations at high risk for CMV disease and on the prophylactic efficacy of valganciclovir. "
5.	Viremia 01/01/2017 - "The results show a significant reduction of CMV viremia in D+/R+ and D-/R+ KTRs after introduction of 3-month prophylaxis with valganciclovir. " 07/01/2009 - "A 12-month CMV prophylaxis with oral valganciclovir is effective in significantly reducing CMV viremia and CMV disease/syndrome in high-risk lung transplant recipients. " 12/01/2009 - "Despite long treatment courses with valganciclovir and documented clearance of viremia, CMV relapse remains common among SOT recipients. " 11/01/2016 - "The aim of this study was to evaluate the incidence of CMV viremia and indirect effects on survival, comparing prophylaxis (V) against preemptive (P) valganciclovir in an older kidney transplant population. " 05/01/2010 - "In conclusion, this study demonstrates that extending valganciclovir prophylaxis (900 mg once daily) to 200 days significantly reduces the incidence of CMV disease and viremia through to 12 months compared with 100 days' prophylaxis, without significant additional safety concerns associated with longer treatment. "

Related Drugs and Biologics

1.	Ganciclovir (Cytovene)
2.	Antiviral Agents (Antivirals)
3.	Foscarnet
4.	Valacyclovir (Valtrex)
5.	Cidofovir (Vistide)
6.	letermovir
7.	Prodrugs
8.	Rituximab (Mabthera)
9.	DNA (Deoxyribonucleic Acid)
10.	maribavir

Related Therapies and Procedures

1.	Therapeutics
2.	Kidney Transplantation
3.	Highly Active Antiretroviral Therapy (HAART)
4.	Transplantation
5.	Chemoprevention